Skip to main content
Log in

Effects of pirarubicin, an antitumor antibiotic, on the cardiovascular system

  • Original Articles
  • Pirarubicin, Cardiovascular System, Vascular Dilation, Histamine
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Summary

In the present study we examined the effects of pirarubicin [(2″R)-4′-0-tetrahydropyranyladriamycin, THP] on a cardiovascular system. An injection of THP (0.39–3.13 mg/kg, i. v.) reduced the mean blood pressure and caused an increase in the respiratory air rate in anesthetized rats. At 1.5×10−6–1.5×10−5 m, THP markedly relaxed a contraction induced by 10−7 m norepinephrine in rat aorta with endothelium but not in that without endothelium. At a dose of 0.02–0.5 mg, THP produced an increase in the contractile force and the perfusion flow of isolated perfused guinea pig hearts. At a higher concentration (4.5×10−5–1.5×10−4 m), it produced a slight increase in the contractile force of the left atria in guinea pigs. This positive inotropic action of THP was inhibited by diphenhydramine (10−6–5×10−5 m), chlorpheniramine (3×10−7–3×10−5 m), and tripelennamine (3×10−7–3×10−5 m) but not by propranolol (10−6 m), cimetidine (10−5 m), diltiazem (10−6 m), or ryanodine (10−8 m). THP given i. v. at 2.5 mg/kg elevated the plasma histamine level in anesthetized dogs. From these data, we conclude that THP mainly relaxed the rat aorta in the presence of endothelium and that at higher concentrations, it increased the contractile force in the cardiac muscle, probably mediated through the release of histamine.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Agata N, Hirano S, Hara U, Urakawa N (1990) A comparison of pirarubicin with other anthracycline antitumor antibiotics on the isolated guinea pig heart and rat aorta. Jpn J Pharmacol 52 [Suppl I]: 174

    Google Scholar 

  2. Bachur NR, Gordon SL, Gee MV (1977) Anthracycline antibiotic augmentation of microsomal electron transport and free radical formation. Mol Pharmacol 13: 901

    Google Scholar 

  3. Bernstein JG, Bachur NR, Thompson WL (1968) Effect of daunomycin on cardiovascular responses to isoproterenol and norepinephrine. Arch Int Pharmacodyn Ther 176: 11

    Google Scholar 

  4. Blum RH, Carter JK (1974) Adriamycin: a new anticancer drug with significant clinical activity. Ann Intern Med 80: 249

    Google Scholar 

  5. Bonnadonna G, Monfardini S, Lena MD, Fassati-Bellani F (1969) Clinical evaluation of Adriamycin, a new antitumor antibiotic. BMJ 3: 503

    Google Scholar 

  6. Bristow MR, Sagemann WS, Scott RH, Billingham ME, Bowder RE, Kernoff RS, Snidow GH, Daniels JR (1980) Acute and chronic cardiovascular effects of doxorubicin in dogs: the cardiovascular pharmacology of drug-induced histamine release. J Cardiovasc Pharmacol 2: 487

    Google Scholar 

  7. Bristow MR, Minobe WA, Billingham ME, Marmor JB, Johnson GA, Ishimoto BM, Sagemann WS, Daniels JK (1981) Anthracycline-associated cardiac and renal damage in rabbits: evidence for mediation by vasoactive substances. Lab Invest 45: 157

    Google Scholar 

  8. Danchev D, Paintrand M, Hayat M, Bourut C, Mathè G (1979) Low heart and skin toxicity of a tetrahydropyranyl derivative of Adriamycin (THP-ADM) as observed by electron and light microscopy. J Antibiot 32: 1085

    Google Scholar 

  9. Doroshow JH (1983) Effect of anthracycline antibiotic on oxygen radical formation in rat heart. Cancer Res 43: 460

    Google Scholar 

  10. Eschalier A, Lavarenne J, Burtin C, Renoux M, Chapuy E, Rodriguez M (1988) Study of histamine release induced by acute administration of antitumor agents in dogs. Cancer Chemother Pharmacol 21: 246

    Google Scholar 

  11. Facchinetti T, Muh-Zange M, Salmona M, Carini M, Remmer H (1982) Further studies on Adriamycin-induced in vitro lipid peroxidation. Chem Biol Interact 38: 357

    Google Scholar 

  12. Furchgott RF, Zawadzki JV (1980) The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 288: 373

    Google Scholar 

  13. Goormaghtigh E, Brasseur R, Ruysschaert JM (1982) Adriamycin inactivates cytochrome C oxidase by exclusion of the enzyme from its cardiolipin essential enviroment. Biochem Biophys Res Commun 104: 314

    Google Scholar 

  14. Hagane K, Akera T, Berlin JR (1988) Doxorubicin: mechanism of cardiodepressant actions in guinea pigs. J Pharmacol Exp Ther 246: 655

    Google Scholar 

  15. Herman EH, Young RSK (1979) Acute cardiovascular alterations induced by low doses of Adriamycin, rubidazone, and daunorubicin in the anesthetized beagle dog. Cancer Treat Rep 63: 1771

    Google Scholar 

  16. Iguchi H, Tone H, Ishikura T, Takeuchi T, Umezawa H (1985) Pharmacokinetics and disposition of 4′-0-tetrahydropyranyladriamycin in mice by HPLC analysis. Cancer Chemother Pharmacol 15: 132

    Google Scholar 

  17. Kobayashi T, Nakayama R, Takatani O, Kimura K (1972) Positive chronotropic and inotropic actions of new antitumor agent Adriamycin and its cardiotoxicity: its special references to myocardial contractile force and the change of the transmembrane action potential. Jpn Circ J 36: 259

    Google Scholar 

  18. Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA (1973) A clinicopathologic analysis of Adriamycin cardiotoxicity. Cancer 32: 302

    Google Scholar 

  19. Machado FRDS, Assem ESK, Ezeamuzie CI (1985) Cardiac anaphylaxis: the role of different mediators: I. Histamine. Allergol Immunopathol (Madr) 13: 259

    Google Scholar 

  20. Majima H (1982) Preliminary phase I study of 4′-0-tetrahydropyranyladriamycin hydrochloride (THP). Proceedings, 13th International Cancer Congress, Seattle, Washington, September 8–15

  21. Majima H, Iguchi H, Tone H (1986) Pharmacokinetics studies on THP-ADM (tetrahydropyranyladriamycin) (in Japanese). Jpn J Cancer Chemother 13: 542

    Google Scholar 

  22. Matsushita Y, Kumagai H, Yoshimoto A, Tone H, Ishikura T (1985) Antitumor activities of (2″R)-4′-0-tetrahydropyranyladriamycin (THP) and its combination with other antitumor agents on murine tumors. J Antibiot 38: 1408

    Google Scholar 

  23. Mhatre R, Herman E, Huidobro A, Waravdekar V (1971) The possible relationship between metabolism and cardiac toxicity of daunomycin and related compounds. J Pharmacol Exp Ther 178: 216

    Google Scholar 

  24. Olson H, Young D, Prieur D, LeRoy R, Reagan R (1974) Electrolyte and morphologic alterations of myocardium in Adriamycin-treated rabbits. Am J Pathol 77: 439

    Google Scholar 

  25. Olson RD, Boerth RC, Gerber JG, Nies AS (1981) Mechanism of Adriamycin cardiotoxicity: evidence for oxidative stress. Life Sci 29: 1393

    Google Scholar 

  26. Rosenoff SH, Brooks E, Bostick F, Young RC (1975) Alterations in DNA synthesis in cardiac tissue induced by Adriamycin in vivo —relationship to fatal toxicity. Biochem Pharmacol 24: 1898

    Google Scholar 

  27. Sakai K, Shiraki Y (1978) A device for recording left ventricular contraction and electrocardiogram in nonworking isolated perfused rat heart. Jpn J Pharmacol 28: 223

    Google Scholar 

  28. Shore PA, Burkhalter A, Cohn VH (1959) A method for the fluorometric assay of histamine in tissues. J Pharmacol Exp Ther 127: 182

    Google Scholar 

  29. Singer JW, Narahara KA, Ritchie JL, Hamilton GW, Kennedy JW (1978) Time- and dose-dependent changes in ejection fraction determined by radionuclide angiography after anthracycline therapy. Cancer Treat Rep 62: 945

    Google Scholar 

  30. Tone H, Kiyosaki T, Nishimori T, Kobayashi F, Nishimura K, Morino H, Tsuchiyama M (1986) General pharmacology of (2″R)-4′-0-tetrahydropyranyladriamycin, a new antitumor antibiotic (in Japanese). Jpn J Antibiot 39: 547

    Google Scholar 

  31. Tone H, Hirano S, Shirai M, Kumagai H, Okajima Y, Wakabayashi T (1986) Effect of (2″R)-4′-0-tetrahydropyranyladriamycin, a new antitumor antibiotic, on the cardiac function of hamsters (in Japanese). Jpn J Antibiot 39: 547

    Google Scholar 

  32. Unverferth DV, Magorien RD, Unverferth BP, Talley RL, Balcerzak SP, Baba N (1981) Human myocardial morphologic and functional changes in the first 24 hours after doxorubicin administration. Cancer Treat Rep 65: 1093

    Google Scholar 

  33. Villani F, Piccinini F, Merelli P, Favalli L (1978) Influence of Adriamycin on calcium exchangeability in cardiac muscle and its modification by ouabain. Biochem Pharmacol 27: 985

    Google Scholar 

  34. Wakabayashi I, Hatake K, Kakishita E (1989) Vasocontractile action of daunorubicin. J Pharm Pharmacol 41: 801

    Google Scholar 

  35. Wakabayashi I, Sakamoto K, Kakishita E (1990) Potentiating effect of daunorubicin on vasocontractile responses to KCl and BAY K 8644 in rat aorta. J Pharm Pharmacol 42: 716

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hirano, Si., Agata, N., Hara, Y. et al. Effects of pirarubicin, an antitumor antibiotic, on the cardiovascular system. Cancer Chemother. Pharmacol. 28, 266–272 (1991). https://doi.org/10.1007/BF00685533

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00685533

Keywords

Navigation